WuXi Biologics Ireland Achieves Remarkable Success at 2026 Life Sciences Awards

On June 8, 2026, WuXi Biologics (2269.HK), a renowned global Contract Research, Development and Manufacturing Organization (CRDMO), proudly announced its remarkable achievements at the prestigious 2026 Life Sciences Industry Awards held in Dundalk, Ireland. The Ireland site secured the esteemed "Overall Excellence in Life Sciences" award, which stands as the pinnacle of recognition in this influential industry event. This honor is not only a testament to the outstanding capabilities of WuXi Biologics but also a reflection of Ireland's rising prominence in the life sciences sector.

In addition to winning the top accolade, the company celebrated being honored with the "Life Sciences Team of the Year" award. The Manufacturers' Science and Technology (MSAT) team was particularly recognized for their exceptional contributions, demonstrating innovation and operational excellence in biologics manufacturing. Furthermore, the site also received the "Outstanding Contribution Award," complementing their existing accolades and highlighting their comprehensive achievements across various categories.

The Life Sciences Industry Awards serve as a crucial platform for recognizing excellence, innovation, and leadership across Ireland’s pharmaceutical, biotechnology, and medical device sectors. WuXi Biologics was shortlisted in eight different award categories, underscoring the wide-ranging capabilities and successes showcased by its Ireland location. The awards not only celebrate the past accomplishments of the Ireland site but also signal a bright future as one of Europe’s leading biologics manufacturing facilities.

The recognition at these awards solidifies WuXi Biologics Ireland's strategic role within the company's extensive global network. The site is focused on meeting the increasing demand for high-quality biologics manufacturing, providing reliable and flexible solutions that cater to the lifecycle of global clients throughout drug development and commercialization.

These recent accolades build upon a series of significant milestones achieved by the Ireland site over the past few years. This includes obtaining critical certifications, such as HPRA GMP authorization and EMA approval, which validate the site’s capabilities in commercial manufacturing of innovative biologic products. Since its inception, WuXi Biologics Ireland has emerged as one of Europe’s most advanced biologics manufacturing facilities, demonstrating excellence in operational performance and innovation.

Among the other prestigious awards received, the Ireland site previously won the ISPE Facility of the Year Award and the Operational Excellence in Life Sciences Award, both illustrating its expanding role in supporting global biologics development and commercial manufacturing. WuXi Biologics is committed to further advancing Ireland’s robust life sciences ecosystem, continuing to foster innovation and operational excellence.

With a global manufacturing footprint extending through locations in China, the United States, Ireland, Germany, and Singapore, WuXi Biologics operates 24 drug substance (DS) facilities and 18 drug product (DP) facilities. This integrated network empowers collaboration and dual-sourcing solutions for clients, covering everything from clinical development to commercial-scale manufacturing — all while maintaining the highest quality standards. As of 2025, WuXi Biologics successfully passed 46 regulatory inspections worldwide, including 22 audits from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), proudly achieving a 100% success rate with no critical findings.

WuXi Biologics (stock code 2269.HK) is dedicated to providing cutting-edge services that enable partners to discover, develop, and manufacture biologics from inception to market, benefiting patients globally. With over 13,000 professionals across various countries, the company combines deep expertise and knowledge in biological research, technical innovation, and operational excellence to deliver tailored solutions designed to meet clients' unique requirements.

As part of its long-term vision, WuXi Biologics recognizes sustainability as a cornerstone for growth. The company continually strives for technological advancement, offering Green CRDMO solutions while adhering to high Environmental, Social, and Governance (ESG) standards. Their commitment to shared value creation reflects positively on various stakeholders, promoting responsible practices across the entire value chain.

For more detailed insights into WuXi Biologics and its initiatives, please visit www.wuxibiologics.com.